Fibrosis

Nordic touts PRO-C6 biomarker for heart failure clinical trials
By LabPulse.com staff writers
In collaboration with Bristol Myers Squibb and the University of Pennsylvania, researchers combined analyses of six independent cohorts of HFpEF patients from around the globe, which are being evaluated with the PRO-C6 biomarker.
September 13, 2022
2022 09 14 21 40 5599 Heart Pulmonary Trunk 400
Roche, Nordic Bioscience partner on tissue disease markers
By LabPulse.com staff writers
According to Nordic, the extracellular matrix markers it develops are essential for chronic diseases involving tissue fibrosis and inflammation, and the collaboration with Roche will facilitate better clinical decisions in drug development and patient selection for precision medicine.
June 15, 2022
2022 06 16 19 33 6973 Fat Tissue Adipocytes 400
PathAI to present AI pathology studies at London liver congress
By LabPulse.com staff writers
The presentation abstracts describe the use of a new machine learning-enabled continuous scoring system for nonalcoholic steatohepatitis (NASH), the firm said.
June 8, 2022
2021 04 27 15 25 5437 Pathology Digital Workstation Microscope 400
Siemens launches ELF test in the U.S. for NASH assessment
By LabPulse.com staff writers
The ELF test is ordered by a physician and generates a numeric score that has been proven to assess prognosis in patients with advanced fibrosis (F3 or F4) due to NASH. The test is now commercially available after receiving de novo marketing authorization from the U.S. Food and Drug Administration (FDA) in August 2021.
January 25, 2022
2019 08 20 22 16 4501 Liver Anatomy 400
Siemens gets FDA nod for ELF test for liver fibrosis
By LabPulse.com staff writers
ELF is a noninvasive blood test intended for use with the company's Advia Centaur XP immunoassay system. The test provides a numeric score that is automatically generated via an algorithm and is used to assess the likelihood of progressing to cirrhosis and liver-related clinical events in patients with severe or advanced fibrosis (F3 or F4) due to nonalcoholic steatohepatitis (NASH).
August 23, 2021
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Urine test could assess cystic fibrosis's effects on the kidneys
By LabPulse.com staff writers
The study accomplished several things: It identified excretion as the mechanism of secretin-induced urinary bicarbonate, explained metabolic alkalosis in patients with cystic fibrosis, and suggested feasibility of an in vivo human cystic fibrosis urine test to validate drug efficacy.
July 23, 2020
2019 05 02 19 24 6251 Lab Urine Test 400
FIB-4 blood biomarker predicts risk of developing severe liver disease
By Rebekah Moan
The research team led by Dr. Hannes Hagstrom, a hepatologist at the Karolinska University Hospital and docent at Karolinska Institutet in Sweden, calculated FIB-4 at two time points within five years to determine whether doing so could predict the risk of cirrhosis. They found yes, it could: An increase of one unit in FIB-4 boosted the risk of severe liver disease (adjusted hazard ratio (aHR)=1.81, 95% confidence interval (CI) = 1.67-1.96).
July 6, 2020
2019 08 20 22 16 4501 Liver Anatomy 400
ACMG updates lab standards on cystic fibrosis gene testing
By LabPulse.com staff writers
The new ACMG document published in Genetics in Medicine includes information on what to test, how to test, and what to report. It includes revised information about cystic fibrosis and the CFTR gene, new testing considerations and methodologies, and updated recommendations for the interpretation and reporting of test results.
May 17, 2020
2020 05 18 16 52 1568 Girl Mask Cystic Fibrosis 400
Veracyte licenses gene signature for idiopathic pulmonary fibrosis
By LabPulse.com staff writers
Developed by Yale's Dr. Naftali Kaminski and colleagues, the test predicts rapid disease progression associated with IPF. Experience with the gene signature in a multicenter study was published by Kaminski et al in Lancet Respiratory Medicine (November 2017, Vol. 11, pp. 857-868). Some 200,000 patients in the U.S. and Europe are evaluated for IPF and other interstitial lung diseases every year and knowing the severity of the disease could help guide them to the right treatments, the company noted.
April 23, 2020
2020 04 23 16 30 3223 Veracyte N Counter D Xsystem Angled D Xscreen 400
Veracyte licenses NanoString diagnostic platform in $50M deal
By LabPulse.com staff writers
Per the deal, NanoString is due another $10 million as Veracyte's tests are launched on the platform commercially. NanoString's platform enables the simultaneous analysis of RNA, DNA, or protein targets for up to 800 genes.
December 3, 2019
2019 07 08 18 08 5459 Men Working Business 400
Siemens offers liver fibrosis blood test in U.S.
By LabPulse.com staff writers
Siemens' ELF test analyzes quantitative measurements taken from a patient's blood sample for three markers of liver fibrosis: hyaluronic acid (HA), amino-terminal propeptide of type III procollagen (PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-1).
November 25, 2019
2019 07 29 20 37 6243 Siemens Rsna 2018 400
Study shows baby steps toward liquid biopsy for pediatric fatty liver disease
By Emily Hayes
A group affiliated with the multicenter European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD) showed the association of certain fats in the blood with fatty liver on liver biopsies in a poster presentation of 67 patients at the meeting, which was held June 5 to 8 in Glasgow, Scotland. This shows potential for developing a commercial test for the presence of nonalcoholic steatohepatitis (inflammation) and fibrosis (scarring) as an alternative to an invasive liver biopsy within five years, the researchers concluded.
June 9, 2019
2019 06 07 20 09 9827 Mann Fattyliverimage Wikicommon 20190607205447
Page 1 of 1